Moderately to severely active Crohn's Disease research hub
7 indexed studies · 1 currently recruiting
- recruitingPhase III
A study of guselkumab versus risankizumab in participants with moderately to severely active Crohn's Disease
This study compares two approved medicines, guselkumab and risankizumab (Skyrizi), for adults with moderate to severe Crohn's Disease. Researchers want to see which one works better to reduce inflammation and symptoms, especially for those who haven't responded to other treatments.
United Kingdom · Austria · Belgium - recruitingPHASE4
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
This study looks at new ways to treat Crohn's disease using a gentle scan called intestinal ultrasound. It aims to see if targeting 'transmural healing' – healing all layers of the bowel wall – alongside other measures, works better than standard care for people with moderately to severely active Crohn's.
United States · Australia · Belgium - authorisedTherapeutic confirmatory (Phase III)
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
This study compares two existing medicines, Guselkumab and Risankizumab (also known as Skyrizi), for adults with Crohn's disease that is moderate to severe. It aims to see which medicine works better and is safer over time to help people feel much better.
Slovakia · Germany · Denmark - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants with Moderately to Severely Active Crohn’s Disease
This study is looking at a medicine called Stelara for children and teenagers with Crohn's disease. It wants to see if Stelara helps them feel better and stay well. Participants will first receive the medicine through a drip, and then by an injection under the skin.
Hungary · Germany · Belgium - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
This study is looking at a medicine called ozanimod for people with Crohn's disease that is moderate to severe. It wants to see how well the medicine helps reduce their symptoms and improve their gut health over a long period. Researchers will also check how it affects COVID-19 antibody levels.
Germany · Hungary · Slovakia - ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Participants with Moderately to Severely Active Crohn’s Disease with an Inadequate Response to Conventional Therapy
This study is looking at a new medicine called Zeposia for children and young people with Crohn's disease that hasn't responded well to other treatments. Researchers want to see if Zeposia can help improve symptoms and how safe it is over time.
France · Poland · Spain - ongoing, recruitingTherapeutic confirmatory (Phase III)
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
This study is looking into a new medication called Ozanimod for people with moderately to severely active Crohn's disease. Researchers want to see if it can help keep symptoms under control and reduce inflammation in the gut over time.
France · Bulgaria · Czechia